HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

International Business Floats Perrigo Q2 Sales As Market Uncertainties Cloud Americas Region

Executive Summary

OTC drug private label/store brand giant reports April-June overall net sales of $981m, up 3.4%. As its Americas business organic sales slipped 1.4% to $622m, international business sales grew 11.7% to $359m.

You may also be interested in...



US Q3 Consumer Health Earnings Preview: Helm Changes, Supply Challenges, Separation Plan

July-September results for sales of OTC drugs, supplements and personal care products will come with CEO leaving J&J and P&G, a new leader for Perrigo Americas, Bausch Health likely offering Bausch + Lomb separation details and a cloud of rising costs related to supplies.

Who You Gonna Call For US Oral Contraceptive Switch? Former FDA Official Heads Perrigo Americas

Jim Dillard, chief scientific officer for Perrigo since 2019, moves to head the North American business with research and development experience as well as a regulatory background from his work at the FDA.

Colgate Stays Course On Earnings Forecast Against Stormy Headwinds From Costs

Higher material and packaging costs in North America drove Colgate’s Q2 operating profit down 21%. Oral care sales were the bright spot in an otherwise difficult quarter in North America, where total sales declined 4% due to COVID-related demand in 2020 and competitive pressure.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS151647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel